Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
Published: | Updated:
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Hang Quach, MBBS, MD, FRACP, FRCPA
Advertisement
Articles by Hang Quach, MBBS, MD, FRACP, FRCPA
Advertisement
Latest Updated Articles
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple MyelomaPublished: June 2nd 2025 | Updated: June 3rd 2025
Advertisement
Advertisement
Trending on CancerNetwork
1
Will The FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma?
2
FDA Grants Tentative Approval to PNT2003 for GEP-NETs
3
FDA Grants Pre-Market Approval to AI Device for Breast Cancer Surgery
4
DURGA-1 Trial Shows Encouraging Results With Novel Multiple Myeloma Agent
5